These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 34643917)

  • 21. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
    Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A
    Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benefits of Adding Glucagon-Like Peptide 1 Receptor Agonists to Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetic Patients With Atherosclerotic Disease and Heart Failure.
    Lopez PD; Bhatia K; Bohra C; Mahmood K; Baruch L; Eng C
    Am J Cardiol; 2022 Oct; 181():87-93. PubMed ID: 35963825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
    Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS
    Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
    Packer M
    Am J Med; 2018 May; 131(5):461-463. PubMed ID: 29309741
    [No Abstract]   [Full Text] [Related]  

  • 25. [Combination therapy with SGLT2 inhibitor and GLP-1 receptor agonist in type 2 diabetes].
    Scheen AJ
    Rev Med Suisse; 2019 Aug; 15(659):1436-1441. PubMed ID: 31436058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epicardial Fat in the Maintenance of Cardiovascular Health.
    Wu Y; Zhang A; Hamilton DJ; Deng T
    Methodist Debakey Cardiovasc J; 2017; 13(1):20-24. PubMed ID: 28413578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community.
    Nelson AJ; Pagidipati NJ; Aroda VR; Cavender MA; Green JB; Lopes RD; Al-Khalidi H; Gaynor T; Kaltenbach LA; Kirk JK; Lingvay I; Magwire ML; O'Brien EC; Pak J; Pop-Busui R; Richardson CR; Reed M; Senyucel C; Webb L; McGuire DK; Granger CB
    Circulation; 2021 Jul; 144(1):74-84. PubMed ID: 34228476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.
    Brown E; Heerspink HJL; Cuthbertson DJ; Wilding JPH
    Lancet; 2021 Jul; 398(10296):262-276. PubMed ID: 34216571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epicardial adipose tissue GLP-1 receptor is associated with genes involved in fatty acid oxidation and white-to-brown fat differentiation: A target to modulate cardiovascular risk?
    Dozio E; Vianello E; Malavazos AE; Tacchini L; Schmitz G; Iacobellis G; Corsi Romanelli MM
    Int J Cardiol; 2019 Oct; 292():218-224. PubMed ID: 31023563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epicardial adipose tissue feeding and overfeeding the heart.
    Iacobellis G; Barbaro G
    Nutrition; 2019 Mar; 59():1-6. PubMed ID: 30415157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New glucose-lowering drugs for reducing cardiovascular risk in patients with type2 diabetes mellitus].
    Gorgojo-Martínez JJ
    Hipertens Riesgo Vasc; 2019; 36(3):145-161. PubMed ID: 31079957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
    Yamada T; Wakabayashi M; Bhalla A; Chopra N; Miyashita H; Mikami T; Ueyama H; Fujisaki T; Saigusa Y; Yamaji T; Azushima K; Urate S; Suzuki T; Abe E; Wakui H; Tamura K
    Cardiovasc Diabetol; 2021 Jan; 20(1):14. PubMed ID: 33413348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists.
    Scheen AJ
    Diabetes Res Clin Pract; 2018 Sep; 143():88-100. PubMed ID: 29944969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts.
    Baviera M; Genovese S; Lepore V; Colacioppo P; Robusto F; Tettamanti M; D'Ettorre A; Avanzini F; Fortino I; Nicolucci A; Roncaglioni MC; Giorgino F
    Diabetes Obes Metab; 2021 Jul; 23(7):1484-1495. PubMed ID: 33606897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System.
    Puglisi S; Rossini A; Poli R; Dughera F; Pia A; Terzolo M; Reimondo G
    Front Endocrinol (Lausanne); 2021; 12():738848. PubMed ID: 34745006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epicardial adipose tissue in endocrine and metabolic diseases.
    Iacobellis G
    Endocrine; 2014 May; 46(1):8-15. PubMed ID: 24272604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus.
    Sharma A; Verma S
    Can J Diabetes; 2020 Feb; 44(1):93-102. PubMed ID: 31882322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
    North EJ; Newman JD
    Curr Opin Cardiol; 2019 Nov; 34(6):687-692. PubMed ID: 31436559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human Epicardial Fat Expresses Glucagon-Like Peptide 1 and 2 Receptors Genes.
    Iacobellis G; Camarena V; Sant DW; Wang G
    Horm Metab Res; 2017 Aug; 49(8):625-630. PubMed ID: 28514806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.